A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI

[1]  A. Pedersen,et al.  Oral mucosal lesions in older people: relation to salivary secretion, systemic diseases and medications. , 2015, Oral diseases.

[2]  A. Vissink,et al.  World Workshop on Oral Medicine VI: clinical implications of medication-induced salivary gland dysfunction. , 2015, Oral surgery, oral medicine, oral pathology and oral radiology.

[3]  A Vissink,et al.  The functions of human saliva: A review sponsored by the World Workshop on Oral Medicine VI. , 2015, Archives of oral biology.

[4]  A. Vissink,et al.  World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment , 2015, Clinical Oral Investigations.

[5]  C. Scully,et al.  Antiretroviral therapy: effects on orofacial health and health care. , 2014, Oral diseases.

[6]  L. Brunton.  Goodman & Gilman's The pharmacological basis of therapeutic , 2013 .

[7]  J. Ekström,et al.  Salivary secretion effects of the antipsychotic drug olanzapine in an animal model. , 2013, Oral diseases.

[8]  G. Amarenco,et al.  Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. , 2013, European urology.

[9]  J. McEvoy,et al.  Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. , 2013, The Journal of clinical psychiatry.

[10]  M. Thase,et al.  Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary , 2013, Drugs in context.

[11]  S. Orešković,et al.  Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder--the SOLIDAR study. , 2012, Collegium antropologicum.

[12]  Jin-liang Wang,et al.  Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials , 2012, PloS one.

[13]  R. Shelton,et al.  A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. , 2012, The Journal of clinical psychiatry.

[14]  G. Kay,et al.  Cognitive Effects of Oxybutynin Chloride Topical Gel in Older Healthy Subjects , 2012, Clinical Drug Investigation.

[15]  H. Kusama,et al.  Effects of ritobegron (KUC-7483), a novel β3-adrenoceptor agonist, on both rat bladder function following partial bladder outlet obstruction and on rat salivary secretion: a comparison with the effects of tolterodine. , 2012, Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi.

[16]  D. Sheehan,et al.  Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States , 2012, European Neuropsychopharmacology.

[17]  L. Arnold,et al.  Efficacy and Safety of Duloxetine 30 mg/d in Patients With Fibromyalgia: A Randomized, Double-blind, Placebo-controlled Study , 2012, The Clinical journal of pain.

[18]  C. Mulert,et al.  Drug safety and efficacy evaluation of sertindole for schizophrenia , 2012, Expert opinion on drug safety.

[19]  R. Findling,et al.  Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. , 2012, Journal of child and adolescent psychopharmacology.

[20]  S. Akhondzadeh,et al.  Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. , 2012, The Journal of clinical psychiatry.

[21]  G. Kay,et al.  Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study. , 2012, Clinical drug investigation.

[22]  A. Riva,et al.  Atypical antipsychotics--effects of amisulpride on salivary secretion and on clozapine-induced sialorrhea. , 2012, Oral diseases.

[23]  E. Sacco,et al.  Mirabegron: a review of recent data and its prospects in the management of overactive bladder , 2012, Therapeutic advances in urology.

[24]  P. Agrawal,et al.  A successful treatment strategy for clozapine-induced parotid swelling: a clinical case and systematic review , 2012, Therapeutic advances in psychopharmacology.

[25]  Paul Jahshan,et al.  An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study , 2012, Current medical research and opinion.

[26]  Cornelius Katona,et al.  A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder , 2012, International clinical psychopharmacology.

[27]  M. Mohammadi,et al.  Bupropion versus methylphenidate in the treatment of children with attention‐deficit/hyperactivity disorder: randomized double‐blind study , 2012, Human psychopharmacology.

[28]  P. Maruff,et al.  Evaluation of Cognitive Function in Healthy Older Subjects Treated with Fesoterodine , 2012, Postgraduate medicine.

[29]  R. Sabatowski,et al.  Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study , 2012, Current medical research and opinion.

[30]  P. Villaseca.  Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice , 2012, Climacteric : the journal of the International Menopause Society.

[31]  A. Mangel,et al.  Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review , 2012, Clinical and experimental gastroenterology.

[32]  S. Montgomery,et al.  Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies , 2012, International clinical psychopharmacology.

[33]  H. Eriksson,et al.  Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study , 2012, International clinical psychopharmacology.

[34]  H. Moldofsky,et al.  Effects of Bedtime Very Low Dose Cyclobenzaprine on Symptoms and Sleep Physiology in Patients with Fibromyalgia Syndrome: A Double-blind Randomized Placebo-controlled Study , 2011, The Journal of Rheumatology.

[35]  K. Gadde,et al.  Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) , 2011, Obesity.

[36]  C. Kahler,et al.  Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study. , 2011, Drug and alcohol dependence.

[37]  M. Hochberg,et al.  Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial , 2011, Current medical research and opinion.

[38]  Pasquale Caponnetto,et al.  Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot study , 2011, BMC public health.

[39]  S. Bajwa,et al.  Comparative evaluation of dexmedetomidine and fentanyl for epidural analgesia in lower limb orthopedic surgeries , 2011, Saudi journal of anaesthesia.

[40]  K. Kario,et al.  Central Sympatholytic Drugs , 2011, Journal of clinical hypertension.

[41]  C. English,et al.  Adverse Drug Events Related to Ziprasidone: A Meta‐analysis of Randomized, Placebo‐Controlled Trials , 2011, Pharmacotherapy.

[42]  A. Riva,et al.  Clozapine-induced salivation: interaction with N-desmethylclozapine and amisulpride in an experimental rat model. , 2011, European journal of oral sciences.

[43]  H. Kerstjens,et al.  Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. , 2011, The Journal of allergy and clinical immunology.

[44]  C. Boomershine,et al.  Duloxetine in the management of diabetic peripheral neuropathic pain , 2011, Patient preference and adherence.

[45]  R. Shrivastava,et al.  Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. , 2011, The Journal of clinical psychiatry.

[46]  R. Gur,et al.  Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers , 2011, Psychopharmacology.

[47]  A. Pedersen,et al.  Associations between oral and ocular dryness, labial and whole salivary flow rates, systemic diseases and medications in a sample of older people. , 2011, Community dentistry and oral epidemiology.

[48]  E. Hellriegel,et al.  Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers. , 2011, Clinical therapeutics.

[49]  T. Berl,et al.  Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. , 2011, European journal of endocrinology.

[50]  K. Gadde,et al.  Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[51]  B. Pitrosky,et al.  A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder. , 2011, The primary care companion for CNS disorders.

[52]  D. Staskin,et al.  Development of oxybutynin chloride topical gel for overactive bladder. , 2011 .

[53]  O. Yamaguchi,et al.  Efficacy, Safety and Tolerability of Fesoterodine in Asian Patients with Overactive Bladder , 2011, Lower urinary tract symptoms.

[54]  A. Bouwer.  Combination cold and flu medicines: an overview of autonomic nervous system receptors , 2011 .

[55]  T. Wigal,et al.  Effect Size of Lisdexamfetamine Dimesylate in Adults with Attention-Deficit/Hyperactivity Disorder , 2011, Postgraduate medicine.

[56]  D. Spyker,et al.  Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. , 2011, The Journal of clinical psychiatry.

[57]  Hans Eriksson,et al.  Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial , 2011, International clinical psychopharmacology.

[58]  Howard S. Smith,et al.  Pharmacotherapy for Fibromyalgia , 2010, Front. Pharmacol..

[59]  Douglas Woo,et al.  Extrapyramidal symptoms with concomitant use of amitriptyline and amiodarone in an elderly patient. , 2010, The American journal of geriatric pharmacotherapy.

[60]  G. Koren,et al.  Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. , 2010, American journal of obstetrics and gynecology.

[61]  L. Arnold,et al.  Flexible Dosed Duloxetine in the Treatment of Fibromyalgia: A Randomized, Double-blind, Placebo-controlled Trial , 2010, The Journal of Rheumatology.

[62]  G. Zlateva,et al.  Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies , 2010, BMC family practice.

[63]  R. Conley,et al.  Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder , 2010, BMC psychiatry.

[64]  Erin M. Timpe,et al.  Asenapine: A Novel Atypical Antipsychotic Agent for Schizophrenia and Bipolar I Disorder , 2010 .

[65]  M. Tehrani-Doost,et al.  Efficacy of reboxetine in adults with attention‐deficit/hyperactivity disorder: A randomized, placebo‐controlled clinical trial , 2010, Human psychopharmacology.

[66]  A. Serretti,et al.  Novel Antidepressants and Panic Disorder: Evidence beyond Current Guidelines , 2010, Neuropsychobiology.

[67]  P. Jensen,et al.  Stimulant-Responsive and Stimulant-Refractory Aggressive Behavior Among Children With ADHD , 2010, Pediatrics.

[68]  A. Pedersen,et al.  Associations between labial and whole salivary flow rates, systemic diseases and medications in a sample of older people. , 2010, Community dentistry and oral epidemiology.

[69]  S. Serels,et al.  Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms , 2010, Current medical research and opinion.

[70]  M. Coskun,et al.  Mirtazapine Treatment for Comorbid Anxiety / Depressive Disorders in Young Subjects with Attention-Deficit Hyperactivity Disorder: Case Series , 2010 .

[71]  T. Brown,et al.  Open-Label Administration of Lisdexamfetamine Dimesylate Improves Executive Function Impairments and Symptoms of Attention-Deficit/Hyperactivity Disorder in Adults , 2010, Postgraduate medicine.

[72]  A. Giobbie-Hurder,et al.  Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial , 2010, Menopause.

[73]  F. Greenway,et al.  Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2010, The Lancet.

[74]  A. Walters,et al.  Rotigotine improves restless legs syndrome: A 6‐month randomized, double‐blind, placebo‐controlled trial in the United States , 2010, Movement disorders : official journal of the Movement Disorder Society.

[75]  D. Perng,et al.  An open-label, multicentre study of levocetirizine for the treatment of allergic rhinitis and urticaria in Taiwanese patients. , 2010, The Chinese journal of physiology.

[76]  H. Eriksson,et al.  Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. , 2010, The international journal of neuropsychopharmacology.

[77]  S. Praharaj,et al.  Salivary Flow Rate in Patients With Schizophrenia on Clozapine , 2010, Clinical neuropharmacology.

[78]  S. Nalamachu,et al.  Efficacy and Tolerability of Cyclobenzaprine Extended Release for Acute Muscle Spasm: A Pooled Analysis , 2010, Postgraduate medicine.

[79]  S. Kornstein,et al.  Analysis by Age and Sex of Efficacy Data From Placebo-Controlled Trials of Desvenlafaxine in Outpatients With Major Depressive Disorder , 2010, Journal of clinical psychopharmacology.

[80]  M. Gupta,et al.  Efficacy of olanzapine and sodium valproate given alone or as add-on therapy in acute mania. A comparative study. , 2010, Methods and Findings in Experimental and Clinical Pharmacology.

[81]  A. Vissink,et al.  Dry Mouth, The Malevolent Symptom: A Clinical Guide , 2010 .

[82]  S. Rashiq,et al.  Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. , 2010, Clinical therapeutics.

[83]  E. Vieta,et al.  A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. , 2010, Bipolar disorders.

[84]  A. Mattiasson,et al.  Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible‐dose regimen: results from a randomized study , 2010, BJU international.

[85]  S. Inomata,et al.  Effects of Mexiletine, a CYP1A2 Inhibitor, on Tizanidine Pharmacokinetics and Pharmacodynamics , 2010, Journal of clinical pharmacology.

[86]  A. Eyler,et al.  Milnacipran for the management of fibromyalgia syndrome , 2010, Journal of pain research.

[87]  T. Suppes,et al.  Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. , 2010, Journal of affective disorders.

[88]  Mellar P. Davis,et al.  Methylphenidate Side Effects in Advanced Cancer: A Retrospective Analysis , 2010, The American journal of hospice & palliative care.

[89]  A. Young,et al.  A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). , 2010, The Journal of clinical psychiatry.

[90]  A. Young,et al.  A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). , 2010, The Journal of clinical psychiatry.

[91]  J. Ekström,et al.  Clozapine: Agonistic and Antagonistic Salivary Secretory Actions , 2010, Journal of dental research.

[92]  S. Herschorn,et al.  Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head‐to‐head placebo‐controlled trial , 2010, BJU international.

[93]  Alan Wright,et al.  Duloxetine in the treatment of generalized anxiety disorder , 2009, International journal of general medicine.

[94]  N. Smith,et al.  Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. , 2009, Current therapeutic research, clinical and experimental.

[95]  R. McIntyre,et al.  Asenapine versus olanzapine in acute mania: a double-blind extension study. , 2009, Bipolar disorders.

[96]  E. Lower,et al.  Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. , 2009, Journal of pain and symptom management.

[97]  D. Tu,et al.  Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial , 2009, The Lancet.

[98]  E. Nagata.  [Antidepressants in migraine prophylaxis]. , 2009, Brain and nerve = Shinkei kenkyu no shinpo.

[99]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[100]  Jennifer M. Belavic.  Fesoterodine for the treatment of overactive bladder. , 2009, The Nurse practitioner.

[101]  S. Kraus,et al.  Tolterodine extended release is well tolerated in older subjects , 2009, International journal of clinical practice.

[102]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[103]  Dan J. Stein,et al.  Pharmacotherapy for anxiety disorders in children and adolescents ( Review ) , 2022 .

[104]  V. Milanova,et al.  Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR , 2009, Journal of psychopharmacology.

[105]  W. Aberer.  Desloratadine for the Relief of Nasal and Non-nasal Allergy Symptoms: An Observational Study , 2009, Archives of drug information.

[106]  Y. Homma,et al.  A randomized, double‐blind, placebo‐ and propiverine‐controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder , 2009, International journal of urology : official journal of the Japanese Urological Association.

[107]  M. Wagner,et al.  Rotigotine transdermal system for the treatment of restless legs syndrome , 2009 .

[108]  S. Montgomery,et al.  Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. , 2009, The Journal of clinical psychiatry.

[109]  Rachel Churchill,et al.  Escitalopram versus other antidepressive agents for depression. , 2009, The Cochrane database of systematic reviews.

[110]  E. Constant,et al.  Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. , 2009, The Journal of clinical psychiatry.

[111]  S. Kaplan,et al.  Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. , 2009, Urology.

[112]  C. Pae.  Desvenlafaxine: a new antidepressant or just another one? , 2009, Expert opinion on pharmacotherapy.

[113]  M. Mahoney,et al.  Adverse effects with use of nicotine replacement therapy among quitline clients. , 2009, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[114]  Fuzhou Wang,et al.  Continuous infusion of butorphanol combined with intravenous morphine patient-controlled analgesia after total abdominal hysterectomy: a randomized, double-blind controlled trial , 2009, European journal of anaesthesiology.

[115]  P. Alken,et al.  Effects of Propiverine and Its Metabolite Propiverine-N-Oxide on Bladder Contraction and Salivation in Mini Pigs , 2008, Urologia Internationalis.

[116]  Y. Oba,et al.  Safety, tolerability and risk benefit analysis of tiotropium in COPD , 2008, International journal of chronic obstructive pulmonary disease.

[117]  A. Astrup,et al.  Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[118]  M. Chancellor,et al.  Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. , 2008, Clinical therapeutics.

[119]  P. Herbison,et al.  Anticholinergic drugs, bladder retraining and their combination for urge urinary incontinence: a pilot randomised trial , 2008, International Urogynecology Journal.

[120]  Mary Sano,et al.  Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study , 2008, The Lancet.

[121]  Patrícia Del Vigna de Almeida,et al.  Effects of antidepressants and benzodiazepines on stimulated salivary flow rate and biochemistry composition of the saliva. , 2008, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[122]  A. Bhat,et al.  Management of narcolepsy , 2008, Expert opinion on pharmacotherapy.

[123]  M. Billiard.  Narcolepsy: current treatment options and future approaches , 2008, Neuropsychiatric disease and treatment.

[124]  F. Müller,et al.  Smoking and smoking cessation in Latin America: a review of the current situation and available treatments , 2008, International journal of chronic obstructive pulmonary disease.

[125]  J. Schwartz,et al.  Modafinil in the treatment of excessive sleepiness , 2008, Drug design, development and therapy.

[126]  K. Nakagawa,et al.  Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy. , 2008, Pharmacogenomics.

[127]  M. Pollack,et al.  Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. , 2008, Archives of general psychiatry.

[128]  Serena J Counsell,et al.  Evidence from in vivo 31-phosphorus magnetic resonance spectroscopy phosphodiesters that exhaled ethane is a biomarker of cerebral n-3 polyunsaturated fatty acid peroxidation in humans , 2008, BMC psychiatry.

[129]  P. Keck,et al.  High‐dose escitalopram in the treatment of binge‐eating disorder with obesity: a placebo‐controlled monotherapy trial , 2008, Human psychopharmacology.

[130]  B. Begović,et al.  Fixed combination lisinopril plus hydro-chlorothiazide in the treatment of essential arterial hypertension: an opened, multi-centre, prospective clinical trial. , 2007, Bosnian journal of basic medical sciences.

[131]  D. Staskin,et al.  Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions , 2007, International journal of clinical practice.

[132]  A. Chugh,et al.  Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model. , 2007, European journal of pharmacology.

[133]  P. Abrams,et al.  Muscarinic receptor antagonists for overactive bladder , 2007, BJU international.

[134]  L. Rohde,et al.  Aripiprazole in Juvenile Bipolar Disorder Comorbid with Attention-Deficit/Hyperactivity Disorder: An Open Clinical Trial , 2007, CNS Spectrums.

[135]  J. Biederman,et al.  An Open-Label Trial of Aripiprazole Monotherapy in Children and Adolescents with Bipolar Disorder , 2007, CNS Spectrums.

[136]  J. Monti,et al.  Eszopiclone: its use in the treatment of insomnia , 2007, Neuropsychiatric disease and treatment.

[137]  A. Carlsson,et al.  An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms , 2007, Human psychopharmacology.

[138]  A. Srinivas,et al.  Comparative clinical study of the efficacy and safety of a S-metoprolol ER tablet versus a racemate metoprolol ER tablet in patients with chronic stable angina. , 2007, International journal of clinical pharmacology and therapeutics.

[139]  G. Manfro,et al.  The efficacy of milnacipran in panic disorder: an open trial , 2007, International clinical psychopharmacology.

[140]  L. Arnold,et al.  Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder* , 2007, Current medical research and opinion.

[141]  W. Hellstrom,et al.  Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation , 2007, Therapeutics and clinical risk management.

[142]  S. Matthews,et al.  Efficacy of Noradrenergic and Serotonergic Antidepressants in Chronic Back Pain: A Preliminary Concentration-Controlled Trial , 2007, Journal of clinical psychopharmacology.

[143]  D. Goldstein.  Duloxetine in the treatment of major depressive disorder , 2007, Neuropsychiatric disease and treatment.

[144]  L. Patton,et al.  World Workshop on Oral Medicine IV: Process and methodology for systematic review and developing management recommendations. Reference manual for management recommendations writing committees. , 2007, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[145]  C. J. Halas.  Cost–effectiveness of eszopiclone for the treatment of chronic insomnia , 2007, Expert review of pharmacoeconomics & outcomes research.

[146]  M. Wulster-Radcliffe,et al.  A retrospective pooled analysis of duloxetine safety in 23 983 subjects , 2007, Current medical research and opinion.

[147]  L. Defebvre,et al.  Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[148]  W. Zatónski,et al.  Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. , 2006, Pharmacological reports : PR.

[149]  H. Kang,et al.  Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People , 2006, Yonsei medical journal.

[150]  G. P. Herbison,et al.  Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. , 2006, The Cochrane database of systematic reviews.

[151]  S. Montgomery,et al.  Escitalopram versus venlafaxine XR in the treatment of depression , 2006, International clinical psychopharmacology.

[152]  D. Kajdasz,et al.  Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics , 2006, International clinical psychopharmacology.

[153]  D. Stewart,et al.  Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. , 2006, Journal of affective disorders.

[154]  M Pirmohamed,et al.  Adverse drug reactions in hospital in‐patients: a pilot study , 2006, Journal of clinical pharmacy and therapeutics.

[155]  F. López-Muñoz,et al.  Reboxetine Addition in Patients With Mirtazapine-resistant Depression: A Case Series , 2006, Clinical neuropharmacology.

[156]  S. Yamada,et al.  Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice. , 2006, Biological & pharmaceutical bulletin.

[157]  R. Dmochowski,et al.  Efficacy and tolerability of tolterodine extended‐release in continent patients with overactive bladder and nocturia , 2006, BJU international.

[158]  J. Biederman,et al.  A Randomized, Placebo-Controlled Trial of OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder , 2006, Biological Psychiatry.

[159]  C. Roehrborn,et al.  Efficacy and tolerability of tolterodine extended‐release in men with overactive bladder and urgency urinary incontinence , 2006, BJU international.

[160]  A. Daly,et al.  Desloratadine for allergic rhinitis , 2006, Expert review of clinical immunology.

[161]  M. Välimäki,et al.  Effects of alendronate and hormone replacement therapy, alone and in combination, on saliva, periodontal conditions and gingival crevicular fluid matrix metalloproteinase-8 levels in women with osteoporosis. , 2006, Oral diseases.

[162]  W. Jost,et al.  Duloxetine in the treatment of stress urinary incontinence , 2005, Therapeutics and clinical risk management.

[163]  K. Goto,et al.  Effects of Byakko-ka-ninjin-to on salivary secretion and bladder function in rats. , 2005, Journal of ethnopharmacology.

[164]  C. Adams,et al.  Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials , 2005, BMC medicine.

[165]  R. Armstrong,et al.  Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies. , 2005, The Journal of urology.

[166]  Aaron Vinik.  CLINICAL REVIEW: Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. , 2005, The Journal of clinical endocrinology and metabolism.

[167]  W. van der Vijgh,et al.  Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule , 2005, British Journal of Cancer.

[168]  A. Giglio,et al.  Low-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot study , 2005, Supportive Care in Cancer.

[169]  H. Grunze,et al.  A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. , 2005, The Journal of clinical psychiatry.

[170]  C. Ekmekcioglu,et al.  Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[171]  Roger Chou,et al.  Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. , 2004, Journal of pain and symptom management.

[172]  B. Nauntofte,et al.  Effects of furosemide and bendroflumethiazide on saliva flow rate and composition. , 2004, Archives of oral biology.

[173]  J. Corcos,et al.  A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. , 2004, Clinical therapeutics.

[174]  C. Scully,et al.  Adverse drug reactions in the orofacial region. , 2004, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[175]  W. Dierkes,et al.  Efficacy and safety of venlafaxine ER vs. amitriptyline ER in patients with major depression of moderate severity. , 2004, Pharmacopsychiatry.

[176]  S. Batchelder,et al.  Citalopram in the treatment of dysthymic disorder , 2004, International clinical psychopharmacology.

[177]  M Sculpher,et al.  A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. , 2004, Health technology assessment.

[178]  Y. Homma,et al.  Clinical efficacy and tolerability of extended‐release tolterodine and immediate‐release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo‐controlled trial , 2003, BJU international.

[179]  Pierrette Hondagneu-Sotelo.  Why Employers Love Immigrants: How the Other Half Works: Immigration and the Social Organization of Labor by Roger Waldinger and Michael I. Lichter. Berkeley, CA: University of California Press, 2003, 276 Pages , 2003 .

[180]  C. Scully,et al.  Drug effects on salivary glands: dry mouth. , 2003, Oral diseases.

[181]  C. S. Cbe.  Drug effects on salivary glands: dry mouth , 2003 .

[182]  L. Burrows,et al.  Current pharmacotherapeutic strategies for overactive bladder , 2002, Expert opinion on pharmacotherapy.

[183]  R. Richmond,et al.  Bupropion sustained release. A therapeutic review of Zyban. , 2002, Australian family physician.

[184]  S. Stanton,et al.  Efficacy, Safety, and Tolerability of Extended‐Release Once‐Daily Tolterodine Treatment for Overactive Bladder in Older versus Younger Patients , 2002, Journal of the American Geriatrics Society.

[185]  M. Detke,et al.  Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. , 2002, The Journal of clinical psychiatry.

[186]  S. Sherman,et al.  Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain , 2001, Neurology.

[187]  M. Chancellor,et al.  Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. , 2001, British journal of clinical pharmacology.

[188]  Suck-Won Kim,et al.  Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling , 2001, Biological Psychiatry.

[189]  I. Vanderwaal.  Burning mouth syndrome , 2001 .

[190]  R. Bruun,et al.  An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. , 2001, The Journal of clinical psychiatry.

[191]  M. Humphreys-Beher,et al.  An analysis of parotid salivary gland function with desipramine and age in female NIA Fischer 344 rats , 2001, Experimental Gerontology.

[192]  E. Freye,et al.  Dose-related Effects of Controlled Release Dihydrocodeine on Oro-Cecal Transit and Pupillary Light Reflex , 2001, Arzneimittelforschung.

[193]  G. Tollefson,et al.  Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine , 2001, Biological Psychiatry.

[194]  K. Krishnan,et al.  A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. , 2000, The Journal of clinical psychiatry.

[195]  R. Donahue,et al.  Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. , 2000, The Journal of clinical psychiatry.

[196]  B. Prichard,et al.  I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly. , 2000, Drugs & aging.

[197]  P. Thomas,et al.  A prospective study of atropine premedication in flexible bronchoscopy. , 2000, Australian and New Zealand journal of medicine.

[198]  A. Gelenberg,et al.  Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. , 2000, JAMA.

[199]  R. Conley,et al.  Adverse events related to olanzapine. , 2000, The Journal of clinical psychiatry.

[200]  P. Pianka,et al.  Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine , 2000, Graefe's Archive for Clinical and Experimental Ophthalmology.

[201]  P. Delgado.  Approaches to the enhancement of patient adherence to antidepressant medication treatment. , 2000, The Journal of clinical psychiatry.

[202]  M. Versiani,et al.  Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. , 2000, Journal of clinical psychopharmacology.

[203]  Soler Ma,et al.  [The clozapine-induced hypersalivation and its treatment]. , 1999 .

[204]  Madersbacher,et al.  A placebo‐controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence , 1999, BJU international.

[205]  R. Eglen,et al.  Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. , 1999, Life sciences.

[206]  U. Jonas,et al.  Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation , 1998, World Journal of Urology.

[207]  T. Zuberbier,et al.  Differential effects of new‐generation H1‐receptor antagonists in pruritic dermatoses , 1998, Allergy.

[208]  J. Diamond,et al.  Systemic Adverse Effects of Topical Ophthalmic Agents , 1997, Drugs & aging.

[209]  E. Lee,et al.  Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. , 1997, British journal of urology.

[210]  J. Schuman,et al.  A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. , 1997, Archives of ophthalmology.

[211]  L. Sreebny,et al.  A reference guide to drugs and dry mouth--2nd edition. , 1997, Gerodontology.

[212]  D. Murphy,et al.  Fluoxetine in the Treatment of Premenstrual Dysphoria , 1997, Neuropsychopharmacology.

[213]  C. Shapiro,et al.  Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. , 1997, Journal of Clinical Psychopharmacology.

[214]  K. Goa,et al.  Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. , 1997, Drugs.

[215]  D. Faulds,et al.  Dexfenfluramine , 2013, Drugs.

[216]  H. Carmichael,et al.  Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors. , 1996, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[217]  T. Walters.  Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. , 1996, Survey of ophthalmology.

[218]  P. U. Rani,et al.  An Evaluation of Antidepressants in Rheumatic Pain Conditions , 1996, Anesthesia and analgesia.

[219]  M. Vickers,et al.  Comparison of tramadol with morphine for post-operative pain following abdominal surgery. , 1996, European journal of anaesthesiology.

[220]  V. Ellingrod,et al.  Nefazodone: a new antidepressant. , 1995, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[221]  S. Montgomery.  Safety of mirtazapine: a review , 1995, International clinical psychopharmacology.

[222]  H. Möller,et al.  Antidepressant efficacy in relation to item analysis and severity of depression: a placebo‐controlled trial of fluvoxamine versus imipramine , 1995, International clinical psychopharmacology.

[223]  C. Nemeroff,et al.  Contemporary management of depression. , 1994, The American journal of medicine.

[224]  A. P. Burtner,et al.  Oral side-effects of the most frequently prescribed drugs. , 1994, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.

[225]  C. Jenkins,et al.  Effects of antihypertensive medications on quality of life in elderly hypertensive women. , 1994, American journal of hypertension.

[226]  R. Jurdi,et al.  Antispasmodic drugs to reduce discomfort and colonic spasm during barium enemas: comparison of oral hyoscyamine, i.v. glucagon, and no drug. , 1993, AJR. American journal of roentgenology.

[227]  J. Bennett,et al.  Suppression of dyskinesias in advanced Parkinson's disease , 1993, Neurology.

[228]  J. Bennett,et al.  Suppression of dyskinesias in advanced Parkinson's disease , 1993, Neurology.

[229]  A. Fitton,et al.  Flupirtine , 1993, Drugs.

[230]  B. Krevsky,et al.  Effect of verapamil on human intestinal transit , 1992, Digestive Diseases and Sciences.

[231]  S. Lippmann,et al.  Bupropion: Overview and Prescribing Guidelines in Depression , 1991, Southern medical journal (Birmingham, Ala. Print).

[232]  B. Musch,et al.  Post marketing surveillance of zopiclone: interim analysis on the first 10,000 cases in a clinical study in general practice. , 1990, International clinical psychopharmacology.

[233]  P. Fox,et al.  Effects of furosemide on the oral cavity. , 1989, Gerodontology.

[234]  C. Dawes.  Physiological Factors Affecting Salivary Flow Rate, Oral Sugar Clearance, and the Sensation of Dry Mouth in Man , 1987, Journal of dental research.

[235]  C. Dawes.  Physiological Factors Affecting Salivary Flow Rate, Oral Sugar Clearance, and the Sensation of Dry Mouth in Man , 1987 .

[236]  L. Sreebny,et al.  A reference guide to drugs and dry mouth. , 1986, Gerodontology.

[237]  S. R. Donaldson.  Sialorrhea as a side effect of lithium: a case report. , 1982, The American journal of psychiatry.

[238]  Roger L. Black,et al.  Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1991 .

[239]  Marta Peixoto.  New York University , 1844, The American journal of dental science.

[240]  B. Mintzes,et al.  Information for Physicians and Pharmacists About Drugs That Might Cause Dry Mouth: A Study of Monographs and Published Literature , 2013, Drugs & Aging.

[241]  B. Kalis.  Double-Blind Multicentre Comparative Study of Ebastine, Terfenadine and Placebo in the Treatment of Chronic Idiopathic Urticaria in Adults , 2012, Drugs.

[242]  A. Peláez.  Clinical Efficacy of Ebastine in the Treatment and Prevention of Seasonal Allergic Rhinitis , 2012, Drugs.

[243]  P. Tulkens,et al.  An Analysis of 14 Years of Clinical Data , 2012 .

[244]  W. Storms.  Clinical Studies of the Efficacy and Tolerability of Ebastine 10 or 20mg Once Daily in the Treatment of Seasonal Allergic Rhinitis in the US , 2012, Drugs.

[245]  F. Horak.  Cetirizine/Pseudoephedrine , 2012, Drugs.

[246]  I. Messana,et al.  Saliva and the Control of Its Secretion , 2011 .

[247]  P. Wal,et al.  Drug Interactions and Adverse Drug Reactions in Hospitalized Psychiatric PatientsA Critical Element in Providing Safe Medication Use , 2011 .

[248]  L. Brunton,et al.  Comprar Goodman and gilman's pharmacological basis of therapeutics + dvd with image bank | Laurence Brunton | 9780071624428 | MCGRAW HILL , 2011 .

[249]  S. Inomata,et al.  Effects of mexiletine , a CYP 1 A 2 inhibitor , on tizanidine pharmacokinetics and pharmacodynamics , 2011 .

[250]  J. Sheehan,et al.  Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms. , 2010, Journal of affective disorders.

[251]  R. McIntyre,et al.  Panagides J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord 2009; 11: 815-826 , 2010 .

[252]  P. L. McCormack,et al.  Duloxetine: a review of its use in the treatment of generalized anxiety disorder. , 2009, CNS drugs.

[253]  E. Vieta,et al.  Annals of General Psychiatry BioMed Central Review Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review , 2009 .

[254]  C. Brufau-Redondo,et al.  [Burning mouth syndrome]. , 2008, Actas dermo-sifiliograficas.

[255]  D. Wilfley,et al.  Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. , 2008, The American journal of psychiatry.

[256]  D. M. Robinson,et al.  Mosapride in gastrointestinal disorders. , 2008, Drugs.

[257]  H. Jørgensen,et al.  Validity of self-reported criminal justice system involvement in substance abusing women at five-year follow-up , 2008, BMC psychiatry.

[258]  M. Liebowitz,et al.  Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. , 2008, Current medical research and opinion.

[259]  D. Coghill,et al.  Adverse Effects of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder , 2008, CNS drugs.

[260]  J. Gavrin,et al.  a b s t r a c t Nausea and Vomiting : An Overview of Mechanisms and Treatment in Older Patients , 2007 .

[261]  G. Plosker,et al.  Duloxetine: a review of its use in the treatment of major depressive disorder. , 2007, CNS drugs.

[262]  J. Metello,et al.  Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride , 2007, International Urogynecology Journal.

[263]  Giovambattista De Sarro,et al.  Adverse Effects of Atypical Antipsychotics in the Elderly , 2006, Drugs & aging.

[264]  D. Murdoch,et al.  Sertindole : a review of its use in schizophrenia. , 2006, CNS drugs.

[265]  J. Ballenger.  A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Quetiapine or Lithium as Monotherapy for Mania in Bipolar Disorder , 2006 .

[266]  R. Malone,et al.  Advances in Drug Treatments for Children and Adolescents with Autism and Other Pervasive Developmental Disorders , 2005, CNS drugs.

[267]  V. Plänitz.  Crossover comparison of moxonidine and clonidine in mild to moderate hypertension , 2004, European Journal of Clinical Pharmacology.

[268]  R. Armstrong,et al.  Comparison of Dry Mouth in Women Treated with Extended-Release Formulations of Oxybutynin or Tolterodine for Overactive Bladder , 2004, International Urology and Nephrology.

[269]  G. Plosker,et al.  Atomoxetine , 2012, Drugs.

[270]  P. Abrams,et al.  Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. , 2004, Drugs.

[271]  P. Novotny,et al.  Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. , 2002, Oncology nursing forum.

[272]  M. Michel.  A Benefit-Risk Assessment of Extended-Release Oxybutynin , 2002, Drug safety.

[273]  P. Herbison,et al.  Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. , 2002, The Cochrane database of systematic reviews.

[274]  D. Newnham.  Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing. , 2001, Drug safety.

[275]  K. Wahlbeck,et al.  Clozapine versus typical neuroleptic medication for schizophrenia. , 2000, The Cochrane database of systematic reviews.

[276]  A. Schatzberg.  Clinical efficacy of reboxetine in major depression. , 2000, The Journal of clinical psychiatry.

[277]  J. Staab,et al.  Efficacy of venlafaxine in geriatric depression , 2000, Depression and anxiety.

[278]  S. Sherman,et al.  Effectiveness of tizanidine in neuropathic pain: an open-label study. , 2000, The journal of pain : official journal of the American Pain Society.

[279]  M. A. Soler Roibal,et al.  [The clozapine-induced hypersalivation and its treatment]. , 1999, Actas espanolas de psiquiatria.

[280]  H. Volz,et al.  A Perspective on their Use in the Elderly , 1998 .

[281]  J. Feighner,et al.  Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. , 1998, Journal of affective disorders.

[282]  P. V. van Zwieten.  Centrally acting antihypertensives: a renaissance of interest˙ Mechanisms and haemodynamics , 1997, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[283]  R. Davis,et al.  Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. , 1997, Drugs.

[284]  U. Jonas,et al.  Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. , 1997, World journal of urology.

[285]  P. A. Zwieten.  Centrally acting antihypertensives: a renaissance of interest. Mechanisms and haemodynamics. , 1997 .

[286]  J. Webster,et al.  Aspects of Tolerability of Centrally Acting Antihypertensive Drugs , 1996, Journal of cardiovascular pharmacology.

[287]  P. Benfield,et al.  Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. , 1995, Drugs.

[288]  W. Bowen,et al.  Composition and flow rate of saliva and caries development in young rats following administration of lithium. , 1994, Caries Research.

[289]  J. Zacny,et al.  A dose-response analysis of the subjective, psychomotor and physiological effects of intravenous morphine in healthy volunteers. , 1994, The Journal of pharmacology and experimental therapeutics.

[290]  P A Dekker-de Kiefte,et al.  Diagnosis and Treatment , 2020, Diabetes.

[291]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .